Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Triple combination therapy trial for HR+/HER2− breast cancer halts early due to toxicity concerns (opens in a new tab)

news-medical.net · 2026-09-28

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Two of five claims match the study. This overall rating is based only on the claims we could check. Three claims the study doesn't address.

  • 2 supported
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredDr. Min Yan led an investigator-initiated, single-center, open-label phase Ib/II trial evaluating famitinib, dalpiciclib, and fulvestrant in HR+/HER2− advanced breast cancer.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that this was a phase Ib dose-escalation followed by phase II assessment of famitinib plus dalpiciclib plus fulvestrant in HR+/HER2− advanced breast cancer. However, the profile does not verify Dr. Min Yan’s leadership role, nor the descriptors investigator-initiated, single-center, or open-label. Those may be true in the full paper, but they are not verifiable from the supplied abstract-depth profile.

1

Study evidence

The phase Ib 3+3 dose-escalation selected famitinib 10 mg daily plus dalpiciclib 100 mg with fulvestrant as the recommended phase II dose based on observed dose-limiting toxicities and preliminary efficacy.

“A phase Ib dose-escalation study using a standard 3+3 design was conducted to determine the recommended phase II dose (RP2D).”
2

Study evidence

Confirmed objective response rate in the phase II expansion was 51.9%.51.9% (95% CI: 32.0%–71.3%)

“Phase II subsequently assessed the efficacy and safety of the RP2D.”
Claim 2 of 5Not coveredIn the phase II cohort, the confirmed objective response rate was 51.9% and the disease control rate was 92.6%, meeting the prespecified efficacy threshold for first-stage analysis.View evidenceHide evidence

As statedORR 51.9%; DCR 92.6%

Why this verdict

The abstract-level profile supports the confirmed ORR of 51.9% and states that the phase II first-stage objective response threshold was met. However, the DCR value of 92.6% is not present in the supplied profile, so the full combined claim as stated is not completely verifiable at this evidence depth.

1

Study evidence

Confirmed objective response rate in the phase II expansion was 51.9%.51.9% (95% CI: 32.0%–71.3%)

“Phase II subsequently assessed the efficacy and safety of the RP2D.”
Claim 3 of 5Not coveredSafety findings showed frequent grade 3 or higher hematologic treatment-related adverse events, with nearly all patients requiring dose reductions.View evidenceHide evidence

As stateddecreased neutrophil count 96.4%; decreased leukocyte count 75.0%; decreased platelet count 10.7%

Why this verdict

The profile supports frequent grade ≥3 hematologic treatment-related adverse events, including decreased neutrophil count 96.4%, decreased leukocyte count 75.0%, and decreased platelet count 10.7%. However, the claim that nearly all patients required dose reductions is not provided in the abstract-level profile, making that material part of the claim not verifiable at this depth.

1

Study evidence

Confirmed objective response rate in the phase II expansion was 51.9%.51.9% (95% CI: 32.0%–71.3%)

“Phase II subsequently assessed the efficacy and safety of the RP2D.”
Claim 4 of 5SupportedThe median progression-free survival was 15.7 months and did not appear better than current standard first-line CDK4/6-based regimens such as ribociclib plus fulvestrant.View evidenceHide evidence

As statedmedian PFS 15.7 months; standard comparator cited as 20.5 months

Why this verdict

The profile reports median PFS of 15.7 months and states that median PFS did not demonstrate superiority over standard front-line regimens. The story frames this cautiously as 'did not appear better,' which matches the single-arm, non-comparative nature of the evidence. The specific example of ribociclib plus fulvestrant and the 20.5-month comparator value are not detailed in the supplied profile, but the core claim is supported.

1

Study evidence

Confirmed objective response rate in the phase II expansion was 51.9%.51.9% (95% CI: 32.0%–71.3%)

“Phase II subsequently assessed the efficacy and safety of the RP2D.”
Claim 5 of 5SupportedBecause of safety concerns and lack of clear superiority over standard therapy, patient enrollment was terminated early.View evidenceHide evidence

Why this verdict

The profile states that enrollment was terminated after a comprehensive benefit–risk assessment and links the decision to lack of demonstrated PFS superiority over standard front-line regimens plus overlapping hematologic toxicities. This supports the story’s causal framing that safety concerns and lack of clear superiority drove early termination.

1

Study evidence

Confirmed objective response rate in the phase II expansion was 51.9%.51.9% (95% CI: 32.0%–71.3%)

“Phase II subsequently assessed the efficacy and safety of the RP2D.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Phase II expansion was single-arm and small, with an additional 28 patients enrolled.

    The story mentions single-center design and early termination but does not explicitly report the single-arm nature or the small phase II expansion size of 28 additional patients. This is interpretation-changing because comparisons with standard therapy are indirect.

    From Phase II single-arm expansion at RP2D

  • No concurrent comparator arm was reported, limiting any conclusion about superiority or inferiority versus standard CDK4/6-based therapy.

    The story appropriately avoids claiming a definitive comparative result, but it does not explicitly state the important limitation that the phase II evidence was single-arm with no randomized control group.

    From Phase II single-arm expansion at RP2D

5 things the story did carry across
  • Phase Ib 3+3 dose-escalation selected an RP2D of famitinib 10 mg daily plus dalpiciclib 100 mg with fulvestrant.
  • Confirmed ORR was 51.9% with median PFS 15.7 months, while the first-stage objective response threshold was met but PFS did not show superiority over standard front-line regimens.
  • Grade ≥3 treatment-related adverse events were predominantly hematologic, with high rates of decreased neutrophil and leukocyte counts.
  • Enrollment was terminated following a comprehensive benefit–risk assessment.
  • Exploratory biomarker analyses found comparable ORR and median PFS regardless of PIK3CA or BRCA1/2 mutation status, but abstract-level data lack subgroup counts, effect estimates, and statistical details.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate feasibility, safety, and identify the recommended phase II dose (RP2D) for combining famitinib (angiogenesis TKI) with dalpiciclib (CDK4/6 inhibitor) plus fulvestrant in HR+/HER2- advanced breast cancer.Phase Ib 3+3 dose-escalationExpand

In plain English

Phase Ib dose-escalation (standard 3+3) of famitinib combined with dalpiciclib plus fulvestrant in HR+/HER2- advanced breast cancer assessed dose-limiting toxicities and preliminary efficacy to select a recommended phase II dose (RP2D); the RP2D chosen was famitinib 10 mg daily with dalpiciclib 100 mg plus fulvestrant.

Key findings

  • The phase Ib 3+3 dose-escalation selected famitinib 10 mg daily plus dalpiciclib 100 mg with fulvestrant as the recommended phase II dose based on observed dose-limiting toxicities and preliminary efficacy.
“A phase Ib dose-escalation study using a standard 3+3 design was conducted to determine the recommended phase II dose (RP2D).”
What this piece can’t prove
  • 3+3 designs provide limited precision for toxicity probability estimation and RP2D determination; full trial report would be needed for comprehensive assessment.

1 further detail could not be confirmed from the summary.

2human in vivoEstimate preliminary anti-tumor activity (e.g., ORR, PFS, OS) of the triplet regimen at the RP2D in a phase II expansion.Phase II single-arm expansion at RP2DExpand

In plain English

Phase II single-arm expansion evaluated efficacy and safety of famitinib + dalpiciclib + fulvestrant at the RP2D (famitinib 10 mg daily; dalpiciclib 100 mg) in patients with HR+/HER2- advanced breast cancer. In the expansion (an additional 28 patients enrolled), the confirmed ORR was 51.9% (95% CI 32.0%–71.3%), median PFS 15.7 months (95% CI 7.3–25.4), and 2‑year OS rate 96.3% (95% CI 76.5%–99.5%). Grade ≥3 treatment-related adverse events were predominantly hematologic (decreased neutrophil count 96.4%, decreased leukocyte count 75.0%, decreased platelet count 10.7%). Comparable ORR and median PFS were reported irrespective of PIK3CA or BRCA1/2 mutation status. Enrollment was terminated after a benefit–risk assessment; median PFS did not show superiority over standard front-line regimens and overlapping hematologic toxicities were observed.

Key findings

  • Confirmed objective response rate in the phase II expansion was 51.9%.51.9% (95% CI: 32.0%–71.3%)
  • Median progression-free survival in the phase II expansion was 15.7 months.Median PFS 15.7 months (95% CI: 7.3–25.4)
“Phase II subsequently assessed the efficacy and safety of the RP2D.”
What this piece can’t prove
  • Phase II expansion was single-arm with a relatively small additional enrollment (28 patients reported in abstract).
  • Abstract does not provide full population denominators, duration of follow-up, or detailed subgroup/sample-size breakdowns for biomarker analyses.
  • No concurrent comparator arm reported in phase II; authors state median PFS did not show superiority over standard front-line regimens.
  • High rates of grade ≥3 hematologic toxicity and early termination of enrollment limit assessment of longer-term outcomes and tolerability.
3human in vivoExplore whether key gene mutation status (e.g., PIK3CA, BRCA1/2) is associated with efficacy outcomes on this regimen.Exploratory biomarker/subgroup analysis (within interventional trial)Expand

In plain English

Exploratory biomarker analyses within the trial evaluated PIK3CA and BRCA1/2 mutation status and reported that objective response rate (ORR) and median progression-free survival (PFS) were comparable regardless of PIK3CA or BRCA1/2 mutation status. The abstract provides no subgroup counts, numerical effect estimates by mutation status, or details of genotyping/statistical methods.

Key findings

  • Comparable objective response rates and median progression-free survival were observed regardless of PIK3CA or BRCA1/2 mutation status.
“Exploratory biomarker analyses were performed to evaluate key gene mutations associated with this BC subtype, including PIK3CA and BRCA1/2.”
What this piece can’t prove
  • Exploratory, correlative analyses nested within a trial (not a primary randomized comparison by mutation status).
  • Abstract lacks numerical subgroup data, effect estimates, and statistical testing details.
  • Unclear assay/source (tumor vs blood) and timing of genotyping from abstract content.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 38 candidate papers

And 32 more candidates considered.